Existing backer ShangPharma reinvested in a series B round for the Pfizer-backed macrocyclic peptide drug developer.

Wayra-backed Quit Genius has secured series A funding as it prepares to add alcohol and drug options to its digital smoking and vaping cessation products.

The antibody therapy developer closed a $100m round co-led by Lilly Asia Ventures that will fund phase 3 clinical studies for its lead drug candidates.

Medison Pharma and Partners Healthcare could be in line for exits after the haematological and musculoskeletal disorder therapy developer filed to raise $86.3m.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The pharmaceutical firm was among the investors in a series G round that valued precision medicine technology provider Tempus at $5bn.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Covid-19 Therapeutics Accelerator has launched with $125m to find treatments for the pandemic, $25m of which came from Mastercard.

Ping An-backed health services provider Fullerton could theoretically seek an acquisition deal or spin off its digital division.

UnityPoint’s corporate VC unit backed the series C round for Vida Diagnostics, a lung disease imaging technology provider.